Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Get Free Report)’s share price traded down 3.7% during mid-day trading on Monday . The stock traded as low as $0.43 and last traded at $0.43. 29,671 shares were traded during mid-day trading, a decline of 68% from the average session volume of 93,100 shares. The stock had previously closed at $0.45.
Theriva Biologics Stock Performance
The firm has a market capitalization of $7.55 million, a PE ratio of -0.38 and a beta of 1.45.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC purchased a new position in Theriva Biologics during the 4th quarter valued at about $25,000. Geode Capital Management LLC purchased a new position in shares of Theriva Biologics in the 1st quarter worth approximately $81,000. Finally, BlackRock Inc. purchased a new position in shares of Theriva Biologics in the 1st quarter worth approximately $133,000. Hedge funds and other institutional investors own 6.17% of the company’s stock.
Theriva Biologics Company Profile
Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.
Read More
- Five stocks we like better than Theriva Biologics
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- United Airlines Soars on Earnings Beat
- How to Invest in Blue Chip Stocks
- J.B. Hunt Hits the Skids: Lower Prices to Come
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Theriva Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theriva Biologics and related companies with MarketBeat.com's FREE daily email newsletter.